B. Fischer

发表

Lessons Learned.

B. Fischer, 2016, Schizophrenia bulletin.

The role of antihistaminic effects in the misuse of quetiapine: A case report and review of the literature

D. Boggs, B. Fischer, 2010, Neuroscience & Biobehavioral Reviews.

Risk-taking in schizophrenia and controls with and without cannabis dependence

D. Kelly, R. McMahon, H. Wehring, 2015, Schizophrenia Research.

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

D. Kelly, D. Boggs, R. Buchanan, 2012 .

Clozapine case series.

G. Eckermann, S. C. Armstrong, K. Cozza, 2007, Psychosomatics.

Factor structure of the brief negative symptom scale

J. Gold, R. Buchanan, L. Hong, 2012, Schizophrenia Research.

Hyperdeactivation of the Default Mode Network in People With Schizophrenia When Focusing Attention in Space.

J. Gold, E. Stein, T. Ross, 2016, Schizophrenia bulletin.

The investigator and the IRB: A survey of depression and schizophrenia researchers

B. Fischer, Praveen George, 2010, Schizophrenia Research.

Clozapine Levels Lowered by Modafinil: A Case Report and Brief Review of Modafinil in Schizophrenia

B. Fischer, E. Weiner, 2008 .

Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia

R. Buchanan, B. Fischer, Walter A. Meyer, 2013, Schizophrenia Research.

The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations

D. Kelly, D. Boggs, R. Buchanan, 2011 .

Participants with schizophrenia retain the information necessary for informed consent during clinical trials.

P. Appelbaum, W. Carpenter, B. Fischer, 2013, The Journal of clinical psychiatry.

A summary of important documents in the field of research ethics.

B. Fischer, 2005, Schizophrenia bulletin.

The unofficial myths of schizophrenia.

B. Fischer, 2012, The Journal of nervous and mental disease.

Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia.

Carol Vidal, S. Himelhoch, B. Fischer, 2013, Clinical schizophrenia & related psychoses.

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Julie Kreyenbuhl, Deanna L Kelly, D. Kelly, 2010, Schizophrenia bulletin.

Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.

Michael F. Green, R. Buchanan, B. Kirkpatrick, 2013, Journal of psychiatric research.

Cortical structural abnormalities in deficit versus nondeficit schizophrenia

G. Pearlson, Alan N. Francis, R. Buchanan, 2012, Schizophrenia Research.

Revisiting the Diagnosis of Schizophrenia: Where have we been and Where are We Going?

B. Fischer, William R. Keller, William T. Carpenter, Jr., 2011, CNS neuroscience & therapeutics.

Will The Kraepelinian Dichotomy Survive DSM-V?

W. Carpenter, B. Fischer, 2009, Neuropsychopharmacology.

In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia

S. A. Wijtenburg, L. Rowland, Shaolin Yang, 2015, Neuroscience & Biobehavioral Reviews.

Tacrolimus-induced paranoid delusions and fugue-like state.

J. Chiappelli, N. Krishna, B. Fischer, 2013, General hospital psychiatry.

The Neurobiology of Negative Symptoms and the Deficit Syndrome

B. Kirkpatrick, W. Carpenter, B. Fischer, 2009 .

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

F. Dickerson, D. Kelly, H. Wehring, 2013, BMC Psychiatry.

Subdomains within the negative symptoms of schizophrenia: commentary.

B. Kirkpatrick, B. Fischer, 2006, Schizophrenia bulletin.

The brief negative symptom scale: psychometric properties.

S. Marder, B. Kirkpatrick, D. Daniel, 2011, Schizophrenia bulletin.

The risk of diabetes in deficit schizophrenia.

G. Strauss, Carol Vidal, B. Fischer, 2014, Clinical schizophrenia & related psychoses.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms

D. Kelly, H. Wehring, S. Feldman, 2015, Journal of clinical psychopharmacology.

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial

Grant D. Huang, M. Thase, T. Suppes, 2017, JAMA.

Community Adherence to Schizophrenia Treatment and Safety Monitoring Guidelines

R. Buchanan, B. Fischer, Walter A. Meyer, 2014, The Journal of nervous and mental disease.

Next-generation negative symptom assessment for clinical trials: Validation of the Brief Negative Symptom Scale

J. Gold, R. Buchanan, B. Kirkpatrick, 2012, Schizophrenia Research.

A Review of American Psychiatry Through Its Diagnoses: The History and Development of the Diagnostic and Statistical Manual of Mental Disorders

B. Fischer, 2012, The Journal of nervous and mental disease.

Direct-to-Consumer Marketing : An Attitude Survey of Psychiatric Physicians

A. Slaby, D. Baron, B. Fischer, 2008 .

The role of social media networks in psychotic disorders: a case report.

A. Hackman, Kelly Register-Brown, Nithin Krishna, 2013, General hospital psychiatry.

Integrating frequency and magnitude information in decision-making in schizophrenia: An account of patient performance on the Iowa Gambling Task.

J. Waltz, J. Gold, E. Brown, 2015, Journal of psychiatric research.

Clinical trials of novel psychotropic agents: some caveats

B. Fischer, Tiffany R. Farchione, 2023, World psychiatry : official journal of the World Psychiatric Association.

Recovery From Schizophrenia: An International Perspective

B. Fischer, 2008 .